Trade Arvinas Inc - ARVN CFD

Arvinas, Inc. Company profile

About Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. It uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three lead product candidates are ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. It develops ARV-766, a PROTAC protein degrader for the treatment of men with metastatic castration-resistant prostate.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Arvinas Inc revenues increased from $21.8M to $46.7M. Net loss increased 60% to $191M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 66% to $180.4M (expense), General and administrative increase of 61% to $61.6M (expense).